Braveheart Bio, Inc. (BRVE) Revenue, Earnings & Financial Statements
$18.78NASDAQ: BRVEMarket Cap $1.33B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Braveheart Bio, Inc. most recently reported annual revenue of $0, a net loss of $67.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$0
Operating Expenses
$67.0M
Operating Profit
−$67.0M
Other Income
$0
Interest
$0
Depreciation
$0
Profit Before Tax
−$67.0M
Tax rate (%)
0.0%
Net Profit
−$67.0M
EPS
−$5.32
Quarterly Results — Last 4 Quarters (USD millions)
Metric
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
Operating Expenses
$7.0M
$15.0M
$16.0M
$30.0M
Operating Profit
−$7.0M
−$15.0M
−$16.0M
−$30.0M
Interest
$0
$0
$0
$0
Profit Before Tax
−$6.0M
−$14.0M
−$15.0M
−$26.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
Net Profit
−$6.0M
−$14.0M
−$15.0M
−$26.0M
EPS
$0.00
−$2.08
−$0.30
−$0.51
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$89.0M
Current Assets
$89.0M
Cash
$89.0M
Inventory
$0
Receivables
$0
Fixed Assets
$0
Capital Work in Progress
$0
Investments
$0
Other Assets
$0
Total Liabilities
$5.0M
Current Liabilities
$5.0M
Borrowings
$0
Other Liabilities
$5.0M
Equity
$0
Reserves
$84.0M
Cash Flow Statement — 1 Years (USD millions)
Metric
2025
Operating Cash Flow
$0
Investing Cash Flow
$0
Financing Cash Flow
$0
Net Cash Flow
$0
Free Cash Flow
$0
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.20
EV / EBITDA
-17.77
FCF Yield
-3.67%
Quick Ratio
21.57
Interest Coverage
—
Return 1Y
—
Return 3Y
—
Return 5Y
—
Braveheart Bio, Inc. (BRVE) financials — frequently asked questions
What is Braveheart Bio, Inc.'s annual revenue?
Braveheart Bio, Inc. (BRVE) reported annual revenue of $0 in its most recent fiscal year.
What is Braveheart Bio, Inc.'s net profit?
Braveheart Bio, Inc. (BRVE) reported a net loss of $67.0M in its most recent fiscal year.
What is BRVE EV/EBITDA?
Braveheart Bio, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -17.77. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks